• Official Full Name
  • ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1
  • Background
  • Glycosylation of proteins affects cell-cell interaction, interactions with the matrix, and the functions of;intracellular molecules. ST6GALNAC1 transfers a sialic acid, N-acetylneuraminic acid (NeuAc), in an alpha-2,6 linkage;to O-linked GalNAc residues. The cancer-associated sialyl-Tn (sTn) antigen is formed by ST6GALNAC1-catalyzed;sialylation of GalNAc residues on mucins (Ikehara et al., 1999 (PubMed 10536037); Sewell et al., 2006 (PubMed;16319059)).
  • Synonyms
  • ST6GALNAC1; ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1; sialyltransferase 7 ((alpha N acetylneuraminyl 2,3 beta galactosyl 1,3) N acetyl galactosaminide alpha 2,6 sialyltransferase) A , SIAT7A; alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1; ST6GalNAcI; 6-sialyltransferase 1; 6-sialyltransferase I; Alpha N acetylgalactosaminide alpha 2 6 sialyltransferase 1; Alpha N acetylgalactosaminide alpha 2 6 sialyltransferase; Alpha-N-acetylgalactosaminide alpha-2; GalNAc alpha 2 6 sialyltransferase I; GalNAc alpha-2; HSY11339; SIA7A_HUMAN; Sialyltransferase 7A; SIAT7-A; SIAT7A; ST6 (alpha N acetyl neuraminyl 2 3 beta galactosyl 1 3) N acetylgalactosaminide alpha 2 6 sialyltransferase 1; ST6GalNAc I; STYI; galNAc alpha-2,6-sialyltransferase I; GalNAc alpha-2, 6-sialyltransferase I, long form; sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) A
Source (Host):Mammalian CellsSpecies:Mouse
Product nameRecombinant Mouse ST6GALNAC1 Protein
Source (Host):Mammalian CellsSpecies:Chicken
Product nameRecombinant Chicken ST6GALNAC1
Source (Host):Species:Human
Product nameRecombinant Human ST6GALNAC1 293 Cell Lysate

ST6GALNAC1 Related Articles

Kato, T; Iwamoto, K; et al. Comprehensive DNA methylation and hydroxymethylation analysis in the human brain and its implication in mental disorders. NEUROPHARMACOLOGY 80:133-139(2014).